SIGLEC7 and breast carcinoma: Here we report on the expression of Siglec‐7 and Siglec‐9 and their ligands in TN and ER+ tumors and on Siglec‐7 and Siglec‐9 signalling induced by breast cancer cells to determine their potential as targets for future immunotherapy in breast cancer.